Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

396
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
396
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

808
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
808
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

666
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
666
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

686
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and morbidity of sacrocolpopexy: Robot (RASC) vs Laparoscopy (LSC), A retrospective, monocentric multi-departmental study.

Journal of gynecology obstetrics and human reproduction·2026
Same author

ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

[Prospective controlled study evaluating teleconsultation and tele-semiology for the management of renal colic].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Evaluation of hymenal adhesions resection in the treatment of recurrent post-coital cystitis.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

Does the urologist keep a central place in the medical information delivered to patients?

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

[Prostatic hyperplasia: Evaluation of practices in general practice, dissemination, and impact of recommendations].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Related Experiment Video

Updated: Apr 24, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

16.6K

[Management of benign prostate hyperplasia].

S Lebdai1, A Descazeaud2,

  • 1Service d'urologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|September 10, 2014
PubMed
Summary

Benign prostatic hyperplasia (BPH) frequently affects men over 50, causing lower urinary tract symptoms (LUTS). This study explains the management strategies for LUTS resulting from BPH to improve patient quality of life.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.7K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.2K

Related Experiment Videos

Last Updated: Apr 24, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

16.6K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.7K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.2K

Area of Science:

  • Urology
  • Andrology
  • Gerontology

Context:

  • Benign prostatic hyperplasia (BPH) is a common condition in men over 50 years old.
  • BPH is a primary cause of lower urinary tract symptoms (LUTS).
  • LUTS significantly impact men's quality of life and can lead to serious complications.

Purpose:

  • To outline the comprehensive management of lower urinary tract symptoms (LUTS) specifically caused by benign prostatic hyperplasia (BPH).

Summary:

  • This review details the diagnostic approaches and therapeutic options for managing LUTS in BPH patients.
  • Management strategies encompass medical treatments, minimally invasive procedures, and surgical interventions.
  • The focus is on alleviating symptoms and preventing disease progression.

Impact:

  • Provides clinicians with a guide for effective BPH and LUTS management.
  • Aims to improve the quality of life for aging men experiencing urinary issues.
  • Highlights the importance of timely and appropriate intervention for BPH-related complications.